TYSABRI
Posted Saturday 07 June 2008 - 20:21 PM by David Chan (
MEDIUM
significance )
ATC Code
L04AA23
Warning
Biogen Idec Canada Inc., in consultation with Health Canada, would like to inform you about new safety information regarding the risk of liver injury and hypersensitivity in patients receiving TYSABRITM (natalizumab).
No comments so far